4129.Two
4129.TWO is a medical equipment and supplies company operating in the healthcare services and equipment sector, generating revenue primarily through the distribution and sale of medical products.
Business. 4129.TWO is a medical equipment and supplies company operating in the healthcare services and equipment sector, generating revenue primarily through the distribution and sale of medical products.
Analyst recommendations
4 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
4129.TWO is a medical equipment and supplies company operating in the healthcare services and equipment sector, generating revenue primarily through the distribution and sale of medical products.
The company's capital structure is characterized by a debt-to-equity ratio of 0.5, indicating a relatively balanced mix of debt and equity financing. Its liquidity position is assessed as medium, with a current ratio of 1.72, suggesting the company has sufficient short-term assets to cover its short-term liabilities, but with limited excess. The company's free cash flow is negative at -36,886,000 TWD, which may indicate that the company is investing heavily in its operations or facing operational inefficiencies.
In terms of profitability, the company's return on equity (ROE) is 13.72%, which is a measure of how effectively the company is using shareholders' equity to generate profits. The return on assets (ROA) is 7.19%, indicating that the company is generating a moderate return on its total assets. These figures should be compared against the industry's preferred metrics and cohort medians to determine if the company is outperforming or underperforming its peers.
The company's revenue concentration is not explicitly detailed in the provided data, but the absence of segment-specific revenue data suggests that the company may not have a significant geographic or product diversification. This could pose a risk if the company is overly reliant on a single market or product line.
The company's growth trajectory is not explicitly outlined in the provided data, but the absence of a detailed outlook and the negative free cash flow may suggest that the company is in a phase of investment or facing challenges in generating positive cash flow from operations. The company's capital expenditure of -761,231,000 TWD indicates a significant investment in long-term assets, which could be a sign of expansion or modernization efforts.
The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could affect its ability to meet short-term obligations without additional financing. The dilution risk is low, suggesting that the company is not expected to issue a significant number of new shares that could dilute existing shareholders' equity.
Recent events, such as analyst estimates and recommendations, suggest a positive outlook from the investment community. The mean price target is 141.50 TWD, with a median price target of 141.50 TWD, and a mean recommendation of 1.50, indicating a generally positive sentiment towards the company. The absence of recent filings or transcripts does not provide additional insight into the company's recent activities or strategic direction.
- The company has a balanced capital structure with a debt-to-equity ratio of 0.5.
- The company's ROE of 13.72% indicates strong profitability relative to shareholders' equity.
- The company's liquidity position is medium, with a current ratio of 1.72.
- The company's free cash flow is negative, which may indicate significant investment in operations or inefficiencies.
- The company's growth trajectory is not clearly defined, but the negative free cash flow and significant capital expenditure suggest investment or expansion efforts.
- The investment community has a generally positive outlook, with a mean price target of 141.50 TWD and a mean recommendation of 1.50.
- margin_outlook_rationale: The company's gross profit margin is strong, but the operating margin is moderate, suggesting potential for improvement in cost management.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 6,98 |
| Revenue | —no estimate | —no estimate | 6,7B TWD |
| Operating income | —no estimate | —no estimate | 912,2M TWD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 4129.TWO Market data — financials · 2026-05-26
- United Orthopedic Corp Market data — analyst estimates · 2026-05-26